Published in Pharma Law Weekly, September 13th, 2005
The presentation may be viewed on the U.S. BioDefense website.
U.S. BioDefense is evaluating the neural crest stem cell line and its utilization in human transplantation for commercialization, which can be used to treat brain and spinal cord repair.
Recent advances in stem cell biology have aroused attention by investigators...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2005-09-13)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.